Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.

CONCLUSION: 1,310 men were treated with abiraterone and 3,579 with enzalutamide. In multivariable analysis, CVD risk was increased in men on abiraterone (hazard ratio (HR): 1.19; 95% confidence interval (CI): 1.03-1.38) and in men on enzalutamide (HR: 1.10; 95% CI: 1.01-1.20). Men with a recent CVD (<12 months) including both men on ART as well as comparators had a much higher probability of a new CVD vs men with no prior CVD. CVD risk was mildly increased in men with PCa on GnRH plus abiraterone or enzalutamide vs comparator men on GnRH. Residual confounding and detection bias may at least partly explain this association.
PMID: 33606571 [PubMed - as supplied by publisher]

Source: Acta Oncologica - February 19, 2021 Category: Cancer & Oncology Authors: George G, Vikman H, Gedeborg R, Lissbrant IF, Garmo H, Styrke J, Van Hemelrijck M, Stattin P Tags: Acta Oncol Source Type: research